Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension

Core Insights - Idorsia Ltd has introduced TRYVIO™ (aprocitentan), the first hypertension therapy targeting the endothelin pathway, addressing the need for novel treatments in difficult-to-control hypertension [1][2][3] - TRYVIO is the only endothelin receptor antagonist included in the ACC/AHA clinical practice guidelines, highlighting its significance in hypertension management [2][9] Company Overview - Idorsia aims to challenge medical paradigms by discovering, developing, and commercializing transformative medicines, positioning itself as a leading biopharmaceutical company [19][21] - The company is headquartered in Allschwil, Switzerland, and is listed on the SIX Swiss Exchange under the ticker symbol IDIA [21] Product Details - TRYVIO is a once-daily, orally active dual endothelin receptor antagonist approved in the US for systemic hypertension treatment in combination with other antihypertensives since October 2024 [11] - The drug targets a significant patient population, with approximately 26 million patients in the US potentially eligible for treatment under TRYVIO's indication [3][4] Market Opportunity - The hypertension market presents a substantial opportunity, particularly for patients with difficult-to-control hypertension, which is defined as elevated blood pressure despite the use of multiple antihypertensive drug classes [5][6] - Nearly half of US adults, around 120 million people, have hypertension, with 40 million currently treated with antihypertensive drugs [3] Clinical Insights - Patients with difficult-to-control hypertension face higher risks of cardiovascular events and premature mortality, emphasizing the need for effective treatment options [5] - Idorsia will present scientific findings at the AHA Hypertension Scientific Sessions, showcasing the efficacy of aprocitentan in achieving rapid blood pressure control and reducing urinary albumin-to-creatinine ratio (UACR) [7] Recognition - TRYVIO has been nominated for the 2025 Prix Galien USA Awards in the "Best Pharmaceutical Product" category, reflecting its innovative approach in the pharmaceutical landscape [8]